

Mayne Pharma Group (Australia): Accelerated Non-Renounceable Entitlement Offer Changes in FTSE ASFA Australia Index Series

10 February 2015

Following the announcement of an accelerated non-renounceable entitlement offer for Mayne Pharma Group (Australia, constituent) on 10 February 2015, it will be applied as a Rights Issue ex 12 February 2015 based on 1 per 3.45 at AUD 0.61. FTSE announces the following changes:

Index	Change	Effective From Start of Trading
FTSE ASFA Australia 300 Index	Mayne Pharma Group (MYX, B1BXL8) will remain in the index with an increased shares in issue total of 703,651,301 and an unchanged investability weighting of 96%.	12 February 2015
FTSE ASFA Australia Small Cap Index	Mayne Pharma Group will remain in the index as detailed above.	12 February 2015
FTSE ASFA Australia All-Share ex 100 Index	Mayne Pharma Group will remain in the index as detailed above.	12 February 2015
FTSE ASFA Australia All-Share Index	Mayne Pharma Group will remain in the index as detailed above.	12 February 2015

1) Company's Trading is suspended from 10 February 2015 and is expected to recommence on 12 February 2015.

2) Price adjustment Factor based on the closing as of 9 February 2015 is 0.971107544141252.

For further information or general enquiries please contact us at info@ftse.com or call:

Client Services in UK:	Tel: +44 (0) 20 7866 1810
Client Services in Europe, Middle East & Africa:	Tel: +44 (0) 20 7866 1810
Client Services in US:	New York: (Domestic) + 1 888 747 FTSE (3873) / (International): +1 212 314 1139
Client Services in Asia Pacific:	Hong Kong: + 852 2164 3333 Australia: (Domestic Toll-Free) + 1800 653 680 / (International) + 61 (2) 9293 2864 Japan + 81 (3) 3581 2764

Alternatively please visit our website at www.ftse.com

[Terms of Use](#) | Copyright © FTSE